View : 739 Download: 0

Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD

Title
Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD
Authors
Hwang, JihyeJeong, Jee HyangYoon, Soo JinPark, Kyung WonKim, Eun-JooYoon, BoraJang, Jae-WonKim, Hee JinHong, Jin YongLee, Jong-MinPark, HyuntaeKang, Ju-HeeChoi, Yong-HoPark, GilsoonHong, JinwooByun, Min SooYi, DahyunKim, Yu KyeongLee, Dong YoungChoi, Seong Hye
Ewha Authors
정지향
SCOPUS Author ID
정지향scopusscopus
Issue Date
2019
Journal Title
JOURNAL OF CLINICAL MEDICINE
ISSN
2077-0383JCR Link
Citation
JOURNAL OF CLINICAL MEDICINE vol. 8, no. 3
Keywords
Alzheimer's diseasemild cognitive impairmentbiomarkerscohort studysubjective cognitive decline
Publisher
MDPI
Indexed
SCIE; SCOPUS WOS
Document Type
Article
Abstract
We aimed to present the study design of an independent validation cohort from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's disease (AD) (KBASE-V) and to investigate the baseline characteristics of the participants according to the AD clinical spectrum. We recruited 71 cognitively normal (CN) participants, 96 with subjective cognitive decline (SCD), 72 with mild cognitive impairment (MCI), and 56 with AD dementia (ADD). The participants are followed for three years. The Consortium to Establish a Registry for AD scores was significantly different between all of the groups. The logical memory delayed recall scores were significantly different between all groups, except between the MCI and ADD groups. The Mini-Mental State Examination score, hippocampal volume, and cerebrospinal fluid (CSF) amyloid-beta 42 level were significant difference among the SCD, MCI, and ADD groups. The frequencies of participants with amyloid pathology according to PET or CSF studies were 8.9%, 25.6%, 48.3%, and 90.0% in the CN, SCD, MCI, and ADD groups, respectively. According to ATN classification, A+/T+/N+ or A+/T+/N- was observed in 0%, 15.5%, 31.0%, and 78.3% in the CN, SCD, MCI, and ADD groups, respectively. The KBASE-V showed a clear difference according to the AD clinical spectrum in neuropsychological tests and AD biomarkers.
DOI
10.3390/jcm8030341
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE